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S258 Poster Session IIpotentially reversibe risk factors could lessen the potentially disas-
trous results associated with CDAD.
Clostridium Difficile associated Disease
Characteristic CDAD postive CDAD negative p-valueNumber 83 739
age(range) 60(21-74) 56(18-78) .0687
sex(male/female) 37 444/295 0.410
Allo HSCT vs 30 177
Auto HSCT 53 562 .0232
Cefepime 64/83 496/739 .0831
Pip/Tazo 13/83 134/739 .651
Vancomycin 58/83 397/739 .0051
VRE surveillance positiv 29/83 140/739 .0014
Mortality 7/83 25/739 .0345271
ADENOVIRUS (ADV) INFECTION IN PEDIATRIC ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLOSCT) RECIPIENTS IS A MAJOR INDEPENDENT
FACTOR FOR SIGNIFICANTLY INCREASING THE RISK OF TREATMENT RE-
LATED MORTALITY
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Background: ADV infection is an important cause of morbidity
following alloSCT in children, and the attributable mortality of
disseminated ADV in pediatric alloSCT recipients may exceed
80%. We sought to determine the incidence, risk factors, and
associated outcomes of ADV infection in pediatric AlloSCT re-
cipients.
Methods: We analyzed 123 consecutive pediatric AlloSCT recipi-
ents. Conditioning regimens were diverse; 59 (48%) received
reduced toxicity conditioning while 64 (52%) received a myeloabla-
tive regimen. Conditioning regimens included Alemtuzumab or
ATG in 24 (19.5%) and 65 (52.8%) patients respectively. GVHD
prophylaxis (tacrolimus and mycophenolate mofetil) and CMV pro-
phylaxis (alternating foscarnet and ganciclovir) were as previously
described (Osunkwo/Cairo et al, BBMT 2004; Shereck/Cairo et al,
PBC 2006). ADV was diagnosed by antigen detection or viral cul-
ture, and was defined by the isolation of virus with presence of cor-
relating clinical symptoms. Antigen detection was performed by
direct fluorescent assay from respiratory specimens and enzyme
immunoassay from stool.
Results: Age: median 9.5 (0.33–21 years), male/female: 71/52.
MFD 20%, MUD/UCBT 80%. Mean follow-up was 694 days.
The probability of developing ADV infection was 12.3% (CI95
6.0-18.6) and the median time to infection was 42 days (7-203
days). There were no statistically significant differences in proba-
bility of ADV infection in univariate analysis of risk factors includ-
ing donor source, use of ATG/Alemtuzumab, $ Grade II GVHD,
among others (age, diagnosis, conditioning regimen). The proba-
bility of overall survival (OS) for the entire cohort was 46.3%
(CI95 37.3-55.3). The probability of overall survival (OS) for pa-
tients that experienced ADV infection was 15.4% compared to
50% for those without ADV (p5 0.0286). In multivariate analysis,
several risk factors remained significant for an increased risk of
death including: ablative conditioning (HR 1.9), poor risk (HR
2.1), and most importantly, ADV infection (HR 3.15 [CI95 1.6-
6.18] p5 0.0009).
Conclusions: In this series of pediatric AlloSCT recipients, the de-
velopment of ADV infection was the leading multivariate predictor
of treatment-related mortality. Enhanced surveillance with ADV
PCR and identification of the risk factors associated with poor out-
comes from ADV infection may identify patients who could benefit
from pre-emptive therapeutic interventions including ADV-specific
cellular immunotherapies.272
ELEVATED SERUM LEPTIN LEVEL IN PATIENTS WITH PERSISTENT AN-
OREXIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (ALLO-HSCT)
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Background:Gastrointestinal toxicities, infections and GVHD are
common events among patients who undergo allo-HSCT. Leptin
is a hypothalamic modulator of food intake, and is secreted mainly
from adipose tissue. Additionally, it has been reported that circulat-
ing leptin levels increase during infection and inflammation, in-
cluding with autoimmune diseases. To examine whether leptin
may play a pathophysiological role in the early phase of HSCT,
we measured the serum level of leptin for correlation with clinical
parameters.
Methods: The serum level of leptin was measured using the ELISA
method in 67 patients (35 male, 32 female) who received allo-HSCT
from April 2006 to October 2007. The median age of the patients
was 48 years (range, 17-64). Allo-HSCT (42 BM, 20 PB, 5 cord
blood; 45 unrelated, 22 related) for hematologic diseases (31 AML,
21 lymphoma, 7 ALL, 8 others) was performed using myeloablative
(19 BU/CY, 17 CY/TBI6CA) or reduced-intensity conditioning
(14 Flu/BU/ATG-F 5-10 mg/kg, 9 Flu/BU/2-4 Gy TBI, 8 2CdA
or Flu/BU). GVHD prophylaxis was TAC-based in 45 patients
(67%) and CSP-based in 22 patients (33%). Fifty-eight patients
(87%) also received short-term MTX. We defined persistent an-
orexia as oral intake of less than 50% the basal energy expenditure
after 4 weeks post-HSCT. Fat mass was also measured using an In-
Body S20 body composition analyzer (Biospace Co., Ltd., Seoul,
Korea).
Results: The median levels of serum leptin before the conditioning
regimen, and at 1, 2 and 4 weeks after HSCT were, respectively,
4.4 mg/dL, 9.4 mg/dL, 7.8 mg/dL and 7.1 mg/dL. There was a sig-
nificant correlation between the pre-HSCT leptin level and pre-
HSCT body mass (r5 0.34, P5 0.005). The pre-HSCT leptin level
was higher in females than in males (median 5.4 mg/dL v 3.4 mg/dL,
P5 0.04). Pre-HSCT fat mass was recorded in 60 patients, and this
was significantly correlated with the pre-HSCT leptin level
(r5 0.63, P\0.001). There were 29 patients with persistent an-
orexia, and patients whose leptin level increased after HSCT
(n5 38) tended to have a higher incidence of persistent anorexia
(68% v 41%, P5 0.046). There was no correlation between the in-
cidence of acute GVHD and either the pre-HSCT leptin level or the
increase in leptin.
Conclusions: This study suggests that the elevation of leptin could
be associated with persistent anorexia after allo-HSCT. It may be
possible to develop an effective intervention against anorexia by sup-
pressing this leptin elevation.273
CYCLOSPORINE AREA UNDER THE CURVE (AUC) IN CHILDREN UNDER-
GOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): LIM-
ITED SAMPLING STRATEGY (LSS)
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HSCT outcomes may be optimized by cyclosporine dose adjust-
ment according to systemic exposure (measured by AUC) rather
than trough concentration. We have developed LSSs for predicting
cyclosporine AUC after the initial IV dose in children undergoing
HSCT. The aim of this study was to validate the previously devel-
oped LSSs.
Children undergoing myeloablative HSCT and given cyclospor-
ine q12 h as a 2-hour infusion andmethotrexate/methylprednisolone
for acute GVHD prophylaxis were eligible. Cyclosporine AUC was
determined after the first dose and once weekly until engraftment us-
ing 9 concentration-time points.
The association between cyclosporine AUC using all available
data points (AUC-all) and the AUC values predicted by each LSS
was described using the adjusted coefficient of determination (r2);
